J&J Takes Innovative, If Pricey, Route To Ending Hip Suits

Law360, New York (November 21, 2013, 8:31 PM EST) -- In Tuesday's hip implant deal, Johnson & Johnson took the unusual step of accepting responsibility for most of the plaintiffs' insurance liens for surgery costs, a promise that jacks up — perhaps substantially— its $2.5 billion tab, but removes an obstacle to resolution that has increasingly stymied defendants in mass tort litigation.

The company declares in an overview of the agreement that it “will be responsible for most health care insurance liens for medical costs that are directly associated with the revision surgery” of the estimated...
To view the full article, register now.